PCSK9の抑制は,がんに対する免疫チェックポイント療法を強化する.
PubMedで要約を見る
まとめ
この要約は機械生成です。プロプロテインコンバーターゼサブチリシン/ケキシン9型 (PCSK9) を阻害すると,腫瘍細胞のMHC I発現を増加させ,T細胞の反応を刺激することで,がん免疫チェックポイント療法が強化されます. このアプローチは 患者の治療結果を 改善する見込みを示しています
科学分野
- 免疫学
- 腫瘍学
- 分子生物学
背景
- 免疫チェックポイント療法は,一部の患者のがん生存率を向上させるが,多くの患者では無効である.
- 免疫チェックポイント阻害剤の有効性を高めるための新しい戦略が必要である.
- プロプロテインコンバーターゼサブチリシン/ケキシン型9 (PCSK9) は,コレステロール代謝の重要な調節剤である.
研究 の 目的
- PCSK9を阻害することで,がん免疫チェックポイント療法に対する反応が改善されるかどうかを調べる.
- PCSK9抑制が抗腫瘍免疫に影響するメカニズムを解明する.
主な方法
- ネズミの癌細胞におけるPCSK9遺伝子の 削除
- 抗PD1療法とPCSK9 中和抗体をマウスがんモデルに併用する.
- 腫瘍の成長,T細胞の反応,および主要組織適合性タンパク質クラスI (MHC I) の発現の評価
主要な成果
- PCSK9遺伝子の欠損により,T細胞に依存した方法で腫瘍の成長が弱まり,抗PD1治療の有効性が向上しました.
- 臨床的に承認されたPCSK9抗体は,抗PD1療法と連携して腫瘍の成長を抑制した.
- PCSK9の阻害は,腫瘍細胞のMHC I表面発現を増加させ,細胞毒性T細胞の浸透を促進した.
結論
- PCSK9の阻害は,コレステロール調節機能とは独立したメカニズムを通じて,抗腫瘍免疫を強化する.
- PCSK9はMHC Iと物理的に相互作用し,その溶解体分解を促進し,細胞表面表現を減少させます.
- PCSK9を阻害することは,がんに対する免疫チェックポイント療法の有効性を改善する有望な戦略です.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

